[en] Multiple sclerosis (MS) is a chronic inflammatory disease characterized by multifocal demyelination and axonal damage in the central nervous system (CNS). The disruption of the endothelial blood-brain barrier (BBB) with consecutive transmigration of inflammatory cells into the brain parenchyma is of critical importance in the pathogenesis of MS. The integrity of the BBB and the adjacent network of glial cells partially depends on the assembly of intercellular contacts between astrocytes. We demonstrate that recombinant interferon-gamma (rIFN-gamma), a proinflammatory cytokine critically involved in the disruption of the BBB, downregulates the expression of the cell adhesion molecules N-cadherin and vinculin in astrocytic C6 cells using Western blot and immunofluorescence microscopy. By contrast, IFN-beta1a, an established treatment for relapsing-remitting MS, increases the expression of N-cadherin and vinculin and partly inhibits the downregulation of these adhesion molecules by phytohemagglutinin (PHA)-stimulated IFN-gamma-secreting human T lymphocytes in coculture experiments. In summary, we demonstrate that IFN-beta1a modifies the assembly of N-cadherin- and vinculin-mediated intercellular contacts between astrocytic C6 cells in vitro. This effect may also contribute to the therapeutic action of IFN-beta1a in MS.
Disciplines :
Neurologie
Auteur, co-auteur :
Harzheim, Michael; Department of Neurology, University of Bonn, Sigmund-Freud-Strasse 25, D-53105 Bonn, Germany. neurologie@uni-bonn.de
Altenschmidt, Manuela; Department of Neurology, University of Bonn, Bonn, Germany
HENEKA, Michael ; Department of Neurology, University of Bonn, Bonn, Germany
Schröder, Rolf; Department of Neurology, University of Bonn, Bonn, Germany
Klockgether, Thomas; Department of Neurology, University of Bonn, Bonn, Germany
Schmidt, Stephan; Department of Neurology, University of Bonn, Bonn, Germany
Co-auteurs externes :
yes
Langue du document :
Anglais
Titre :
IFN-beta1a (Rebif) modifies the expression of microfilament-associated cell-cell contacts in C6 glioma cells.
BJARTMAR, C., YIN, X., and TRAPP, B.D. (1999). Axonal pathology in myelin disorders. J. Neurocytol. 28, 383-395.
DE STEFANO, N., NARAYANAN, S., FRANCIS, G.S., ARNAOUTELIS, R., TARTAGLIA, M.C., ANTEL, J.P., MATTHEWS, P.M., and ARNOLD, D.L. (2001). Evidence of axonal damage in early stages of multiple sclerosis and its relevance to disability. Arch. Neurol. 58, 65-70.
MARTIN, R., McFARLAND, H.F., and McFARLIN, D.E. (1992). Immunological aspects of demyelinating diseases. Annu. Rev. Immunol. 10, 153-187.
BALASHOV, K.E., COMABELLA, M., OHASHI, T., KHOURY, S.J., and WEINER, H.L. (2000). Defective regulation of IFN-gamma and IL-12 by endogenous IL-10 in progressive MS. Neurology 55, 192-198.
O'CONNOR, K.C., BAR-OR, A., and HAFLER, D.A. (2001). The neuroimmunology of multiple sclerosis: possible roles of T and B lymphocytes in immunpathogenesis. J. Clin. Immunol. 21, 81-92.
MOORE, K.W., O'GARRA, A., and DE WAAL MALEFYT, R. (1993). Interleukin-10. Annu. Rev. Immunol. 11, 165-190.
LINK, H. (1998). The cytokine storm in multiple sclerosis. Mult. Scler. 4, 12-15.
MONTEYNE, P. (1999). Viral infection of the central nervous system: from experimental model to human application. Ann. Fr. Anest. Reanim. 18, 550-553.
SCHULTZ, R.M. (1987). Interleukin-1 and interferon-gamma: cytokines that provide reciprocal regulation of macrophage and T cell function. Toxicol. Pathol. 15, 333-337.
HARTUNG, H.P. (1996). Pathogenesis of multiple sclerosis: status of research. Wien. Med. Wochenschr. 146, 520-527.
POPKO, B., CORBIN, J.G., BAERWALD, K.D., DUPREE, J., and GARCIA, A.M. (1997). The effects of interferon-gamma on the central nervous system. Mol. Neurobiol. 14, 19-35.
BECK, J., RONDOT, P., and CATINOT, L. (1988). Increased production of interferon-gamma and tumor necrosis factor precedes clinical manifestation in multiple sclerosis: do cytokines trigger off exacerbations? Acta Neurol. Scand. 78, 318-323.
SARCHIELLI, P., ORLACCHIO, A., VICINANZA, F., PELLICCIOLI, G.P., TOGNOLONI, M., SACCARDI, C., and GALLAI, V. (1997). Cytokine secretion and nitrite oxide production by mononuclear cells of patients with multiple sclerosis. J. Neuroimmunol. 80, 76-86.
BECHER, B., GIACOMINI, P.S., PELLETIER, D., McCREA, E., PRAT, A., and ANTEL, J.P. (1999). Interferon-gamma secretion by peripheral blood T-cell subsets in multiple sclerosis: correlation with disease phase and interferon-beta therapy. Ann. Neurol. 45, 247-250.
PETEREIT, H.F., RICHTER, N., PUKROP, R., and BAMBORSCHKE, S. (2000). Interferon-gamma production in blood lymphocytes correlates with disability in multiple sclerosis patients. Mult. Scler. 6, 19-23.
WONG, R.K., BALDWIN, A.L., and HELMARK, R.L. (1999). Cadherin-5 redistribution at sites of TNF-alpha and interferon-gamma-induced permeability in mesenteric venules. Heart Circ. Physiol. 76, 736-748.
MADARA, J.L., and STAFFORD, J. (1989). Interferon-gamma directly affects barrier function of cultured intestinal epithelial monolayers. J. Clin. Invest. 83, 724-727.
COLGAN, S.P., PARKOS, C.A., DELP, C., ARNAOUT, M.A., and MADARA, J.L. (1993). Neutrophil migration across cultured intestinal monolayers is modulated by epithelial exposure to interferon-gamma in a highly polarized fashion. J. Cell. Biol. 120, 785-798.
BARON, J.L., MADRI, J.A., RUDDLE, N.H., HASHIM, G., and JANEWAY, C.A. (1993). Surface expression of an integrin by CD4+ T-cells is required for their entry into brain parenchyma. J. Exp. Med. 177, 57-68.
WEKERLE, H. (1993). T-cell autoimmunity in the central nervous system. Intervirology 35, 95-100.
KERMODE, A.G., THOMPSON, A.J., TOFTS, P., MacMANUS, D.G., KENDALL, B.E., KINGSLEY, D.P., MOSELEY, I.F., RUDGE, P., and McDONALD, W.I. (1990). Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis. Pathogenetic and clinical implications. Brain 113, 1477-1489.
COLOSIMO, M., AMATRUDA, A., and CIOFFI, R.P. (1992). Magnetic resonance imaging in multiple sclerosis: an overview. Ital. J. Neurol. Sci. 13, 113-123.
KAPPOS, L., MOERI, D., RADUE, R.W., SCHOETZAU, A., SCHWEIKERT, K., BARKHOF, F., MILLER, D., GUTTMANN, C.R., WEINER, H.L., CASPERINI, C., and FILIPPI, M. (1999). Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Lancet 353, 964-969.
CALABRESI, P.A., STONE, L.A., BASH, C.N., FRANK, J.A., and McFARLAND, H.F. (1997). Interferon-beta results in immediate reduction of contrast-enhanced MRI lesions in multiple sclerosis patients followed by weekly MRI. Neurology 48, 1446-1448.
PAOLILLO, A., BASTIANELLO, S., FRONTONI, M., GASPERINI, C., GIUGNI, E., CICCARELLI, O., LUCCICHENTI, G., CANNONI, S., and POZZILLI, C. (1999). Magnetic resonance imaging outcome of new enhancing lesions in relapsing-remitting multiple sclerosis patients treated with interferon-beta 1a. J. Neurol. 246, 443-448.
PERSIDSKY, Y. (1999). Model systems for studies of leukocyte migration across the blood-brain barrier. J. Neurovirol. 5, 579-590.
HATTA, K., NOSE, A., NAGAFUCHI, A., and TAKEICHI, M. (1988). Cloning and expression of cDNA encoding a neural calcium-dependent cell adhesion molecule: its identity in the cadherin gene family. J. Cell. Biol. 106, 873-881.
PAYNE, H.R., HEMPERLY, J.J., and LEMMON, V. (1996). N-Cadherin expression and function in cultured oligodendrocytes. Rev. Brain. Res. 97, 9-15.
SCHNADELBACH, O., BLASCHUK, O.W., SYMONDS, M., GOUR, B.J., DOHERTY, P., and FAWCETT, J.W. (2000). N-Cadherin influences migration of oligodendrocytes on astrocyte monolayers. Mol. Cell. Neurosci. 15, 288-302.
ABD-EL-BASSET, E.M., AHMED, I., and FEDOROFF, S. (1991). Actin and actin-binding proteins in differentiating astroglia in tissue culture. J. Neurosci. Res. 30, 1-17.
FONTANA, A., KRISTENSEN, F., DUBS, R., GEMSA, D., and WEBER, E. (1982). Production of prostaglandin E and interleukin-1-like factor by cultured astrocytes and C6 glioma cells. J. Neuroimmunol. 129, 2413-2418.
BRODIE, C., and GOLDREICH, N. (1994). Interleukin-4 modulates the proliferation and differentiation of glial cells. J. Neuroimmunol. 55, 91-97.
RHEINWALD, J.G., and GREEN, H. (1977). Epidermal growth factor and the multiplication of cultured human epidermal keratinocytes. Nature 265, 421-424.
FAIRBANKS, G., STECK, T.L., and WALLACH, D.F. (1971). Electrophoretic analysis of the major polypeptides of the human erythrocyte membrane. Biochemistry 10, 2606-2617.
HARTUNG, H.P., ARCHELOS, J.J., ZIELASEK, J., GOLD, R., KOLTZENBURG, M., REINERS, K.H., and TOYKA, K.V. (1995). Circulating adhesion molecules and inflammatory mediators in demyelination: a review. Neurology 45, 22-32.
HOHLFELD, R. (1997). Biotechnological agents for the immunotherapy of multiple sclerosis. Principles, problems and perspectives. Brain 120, 865-916.
PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. (1998). Randomised, double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 352, 1498-1504.
HALL, G.L., COMPSTON, A., and SCOLDING, N.J. (1997). Beta-interferon and multiple sclerosis. Trends Neurosci. 20, 63-67.
MURARO, P.A., LEIST, T., BIELEKOVA, B., and McFARLAND, H.F. (2000). VLA-4/CD49d downregulated on primed T lymphocytes during interferon-beta therapy in multiple sclerosis. J. Neuroimmunol. 111, 186-194.
SCHULZE, C., and FIRTH, J.A. (1993). Immunohistochemical localization of adherens junction components in blood-brain barrier microvessels of the rat. J. Cell Sci. 104, 773-782.
KNIESEL, U., and WOLBURG, H. (2000). Tight junctions of the blood-brain barrier. Cell. Mol. Neurobiol. 20, 57-76.
GERHARDT, H., LIEBNER, S., REDIES, C., and WOLBURG, H. (1999). N-Cadherin expression in endothelial cells during early angiogenesis in the eye and brain of the chicken: relation to blood-retina and blood-brain barrier development. Eur. J. Neurosci. 11, 1191-1201.
BOLTON, S.J., ANTHONY, D.C., and PERRY, V.H. (1998). Loss of the tight junction proteins occludin and zonula occludens-1 from cerebral vascular endothelium during neutrophil-induced blood-brain barrier breakdown in vivo. Neuroscience 86, 1245-1257.
